标题
Targeting CD137 enhances the efficacy of cetuximab
作者
关键词
-
出版物
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 6, Pages 2668-2682
出版商
American Society for Clinical Investigation
发表日期
2014-05-16
DOI
10.1172/jci73014
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
- (2012) Javier Rodríguez et al. EUROPEAN JOURNAL OF CANCER
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
- (2012) Xuanming Yang et al. MOLECULAR THERAPY
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
- (2011) Steve C. Lee et al. IMMUNOLOGIC RESEARCH
- The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells
- (2011) Rebekka Wehner et al. Journal of Innate Immunity
- EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
- (2011) Patrick J Schuler et al. Journal of Translational Medicine
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells
- (2010) K. Juelke et al. BLOOD
- Human T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement
- (2010) A. Maniar et al. BLOOD
- CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
- (2010) H. Narazaki et al. BLOOD
- Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
- (2010) Raphaël Maréchal et al. BMC CANCER
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
- (2010) Carol M Lee et al. BMC CANCER
- 4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines
- (2010) R. K. Sharma et al. CANCER RESEARCH
- Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo
- (2010) Weijuan Gong et al. Cellular & Molecular Immunology
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- (2010) Li-Xin Qiu et al. EUROPEAN JOURNAL OF CANCER
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Regulation of Granulocyte and Macrophage Populations of Murine Bone Marrow Cells by G-CSF and CD137 Protein
- (2010) Dongsheng Jiang et al. PLoS One
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
- (2009) T. Baessler et al. BLOOD
- Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials
- (2009) Lidan Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
- (2009) Andrés López-Albaitero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb
- (2009) Oihana Murillo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- CD137 Promotes Proliferation and Survival of Human B Cells
- (2009) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer
- (2009) Nicolas Acquavella et al. JOURNAL OF IMMUNOTHERAPY
- Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells
- (2008) S. Agaugue et al. BLOOD
- Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
- (2008) W. Lin et al. BLOOD
- A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
- (2008) Aruna Mani et al. BREAST CANCER RESEARCH AND TREATMENT
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates
- (2008) Nikesh Kotecha et al. CANCER CELL
- Requirement of hypoxia-inducible factor-1 down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
- (2008) X. Li et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now